Peer-Reviewed Publication
Vaccine2025;61127416.August 13, 2025Journal Article
Pseudomonas aeruginosa vaccine identified by the AI-immunology™ platform improves outcomes in a murine biofilm lung infection model.
Stine Hansen1, Kim Thomsen2, Andreas Holm Mattsson3, Pär Comstedt3, Claus Moser4, Oana Ciofu5
1Department of Cancer and Inflammation Research, Institute of Molecular Medicine, University of Southern Denmark, J. B. Winsløws Vej 21.1, 5000 Odense C, Denmark.
2Department of Clinical Microbiology, Zealand University Hospital, Koege, Ingemannsvej 46, 4200 Slagelse, Denmark.
3Evaxion Biotech, Dr Neergaards vej 5F, 2970 Hørsholm, Denmark.
4Department of Clinical Microbiology, Rigshospitalet, Copenhagen University Hospital, Henrik Harpestrengsvej 4A, 2100 Copenhagen, Denmark; Department of Immunology and Microbiology, Costerton Biofilm Centre, Faculty of Health and Medical Sciences, Copenhagen University. Blegdamsvej 3B, 2200 Copenhagen, Denmark.
5Department of Immunology and Microbiology, Costerton Biofilm Centre, Faculty of Health and Medical Sciences, Copenhagen University. Blegdamsvej 3B, 2200 Copenhagen, Denmark. Electronic address: ociofu@sund.ku.dk.
Abstract
The Gram-negative opportunistic bacterial pathogen, Pseudomonas aeruginosa is considered by WHO as a "priority pathogen" for which new antibacterial strategies are urgently needed due to antimicrobial resistance development. In addition, P. aeruginosa is a cause of difficult to treat chronic infections due to its ability to form biofilms. Therefore, pseudomonal vaccines have been proposed as alter…
Create a free account to keep reading
Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.
Want unlimited research access? See Pro plans